| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shaun Jordan, Janelle L Johnson, Karen Regardie, Ruoyan Chen, Vuk Koprivica, Yoshihiro Tadori, Junichi Kambayashi, Hisashi Kitagawa, Tetsuro Kikuch. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Progress in neuro-psychopharmacology & biological psychiatry. vol 31. issue 2. 2007-04-24. PMID:17070976. |
together, these data, whilst preclinical in nature, are consistent with clinical evidence suggesting the favorable antipsychotic profile of aripiprazole, compared with the other clinically ineffective partial agonists, is dependent on its low intrinsic activity at dopamine d(2) receptors. |
2007-04-24 |
2023-08-12 |
human |
| Matthew W Feltenstein, C Anthony Altar, Ronald E Se. Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biological psychiatry. vol 61. issue 5. 2007-04-17. PMID:16806092. |
aripiprazole (abilify) is an atypical antipsychotic drug primarily characterized by partial agonist activity at dopamine (da) d2 receptors and low side effects. |
2007-04-17 |
2023-08-12 |
rat |
| Maarten van den Buuse, Andrea Gogo. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition. The Journal of pharmacology and experimental therapeutics. vol 320. issue 3. 2007-04-09. PMID:17194799. |
the action of aripiprazole could be mediated by its partial agonist properties at 5-ht(1a) receptors or its dopamine d(2)-blocking properties. |
2007-04-09 |
2023-08-12 |
rat |
| Ira D Glick, Vandana Duggal, Charles Hoduli. Aripiprazole as a dopamine partial agonist: positive and negative effects. Journal of clinical psychopharmacology. vol 26. issue 1. 2007-04-03. PMID:16415723. |
aripiprazole as a dopamine partial agonist: positive and negative effects. |
2007-04-03 |
2023-08-12 |
Not clear |
| Espen Molden, Hilde Lunde, Niclas Lunder, Helge Refsu. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Therapeutic drug monitoring. vol 28. issue 6. 2007-02-27. PMID:17164689. |
aripiprazole is a new atypical antipsychotic drug with a partial agonist activity at dopamine 2 and serotonin 1a receptors. |
2007-02-27 |
2023-08-12 |
Not clear |
| Euitae Kim, Kyung-Sang Yu, Joo-Youn Cho, Yong-Wook Shin, So Young Yoo, Young Youn Kim, In-Jin Jang, Sang-Goo Shin, Jun Soo Kwo. Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Human psychopharmacology. vol 21. issue 8. 2007-02-26. PMID:16981227. |
the aim of the present study was to evaluate the effects of polymorphisms in dopamine d2 receptor (drd2) and cytochrome p450 (cyp) 2d6 genes on delta eeg power response to aripiprazole in healthy male volunteers. |
2007-02-26 |
2023-08-12 |
human |
| Jonathan D Urban, Gabriel A Vargas, Mark von Zastrow, Richard B Mailma. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 1. 2007-02-09. PMID:16554739. |
aripiprazole has functionally selective actions at dopamine d2 receptor-mediated signaling pathways. |
2007-02-09 |
2023-08-12 |
Not clear |
| William W Stoop. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Experimental and clinical psychopharmacology. vol 14. issue 4. 2007-02-08. PMID:17115868. |
two human laboratory studies are reviewed that tested the ability of aripiprazole, a novel antipsychotic with partial agonist activity at d2 dopamine receptors, to alter the behavioral effects of stimulants using d-amphetamine as a model agent. |
2007-02-08 |
2023-08-12 |
human |
| Margarita García-Amador, Isabella Pacchiarotti, Marc Valentí, Raul F Sanchez, Jose M Goikolea, Eduard Viet. Role of aripiprazole in treating mood disorders. Expert review of neurotherapeutics. vol 6. issue 12. 2007-01-24. PMID:17181424. |
aripiprazole is a recently released antipsychotic medication that differs from other atypical antipsychotic agents by its mode of action as a dopamine d2 partial agonist. |
2007-01-24 |
2023-08-12 |
Not clear |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Julie Westaway, Ceri H Davies, Charlie Reavill, Mark Hill, Claire Rourke, Michael Newson, Declan N C Jones, Ian T Forbes, Andrew Gribbl. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European journal of pharmacology. vol 546. issue 1-3. 2007-01-11. PMID:16925992. |
aripiprazole and its human metabolite are partial agonists at the human dopamine d2 receptor, but the rodent metabolite displays antagonist properties. |
2007-01-11 |
2023-08-12 |
human |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Julie Westaway, Ceri H Davies, Charlie Reavill, Mark Hill, Claire Rourke, Michael Newson, Declan N C Jones, Ian T Forbes, Andrew Gribbl. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European journal of pharmacology. vol 546. issue 1-3. 2007-01-11. PMID:16925992. |
aripiprazole is a novel antipsychotic drug, which displays partial agonist activity at the dopamine d(2) receptor. |
2007-01-11 |
2023-08-12 |
human |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Julie Westaway, Ceri H Davies, Charlie Reavill, Mark Hill, Claire Rourke, Michael Newson, Declan N C Jones, Ian T Forbes, Andrew Gribbl. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European journal of pharmacology. vol 546. issue 1-3. 2007-01-11. PMID:16925992. |
we have therefore studied the interaction of aripiprazole and its principal rat and human metabolites in both in vitro models of dopamine hd(2) receptor function and affinity, and of in vivo models of dopamine rat d(2) receptor function. |
2007-01-11 |
2023-08-12 |
human |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Julie Westaway, Ceri H Davies, Charlie Reavill, Mark Hill, Claire Rourke, Michael Newson, Declan N C Jones, Ian T Forbes, Andrew Gribbl. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European journal of pharmacology. vol 546. issue 1-3. 2007-01-11. PMID:16925992. |
the human metabolite displayed similar levels of partial agonist activity to aripiprazole at the dopamine hd(2) receptor and displayed similar behavioural profile to aripiprazole in vivo, suggesting that in man the metabolite may maintain the effects of aripiprazole. |
2007-01-11 |
2023-08-12 |
human |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Julie Westaway, Ceri H Davies, Charlie Reavill, Mark Hill, Claire Rourke, Michael Newson, Declan N C Jones, Ian T Forbes, Andrew Gribbl. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European journal of pharmacology. vol 546. issue 1-3. 2007-01-11. PMID:16925992. |
thus care must be taken in ascribing effects seen in vivo with aripiprazole in rats to dopamine d(2) receptor partial agonist activity in man, and that care must also be taken in extrapolating effects seen in rats to man, particularly from long-term studies. |
2007-01-11 |
2023-08-12 |
human |
| Karen E Moeller, Theresa I Shireman, Barry I Lisko. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. The Journal of clinical psychiatry. vol 67. issue 12. 2007-01-09. PMID:17194273. |
aripiprazole is the first of a new generation of antipsychotics that possesses a unique mechanism of action as a partial dopamine agonist. |
2007-01-09 |
2023-08-12 |
Not clear |
| Julia N Heinrich, Julie Brennan, Margaret H Lai, Kelly Sullivan, Geoff Hornby, Mike Popiolek, Li-Xin Jiang, Mark H Pausch, Gary Stack, Karen L Marquis, Terrance H Andre. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. European journal of pharmacology. vol 552. issue 1-3. 2007-01-04. PMID:17056032. |
in all assay modalities, the potencies and intrinsic activities of aplindore were lower than dopamine and higher than aripiprazole. |
2007-01-04 |
2023-08-12 |
human |
| Kimmo Ingman, Johanna Kupila, Petri Hyytiä, Esa R Korp. Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol and alcoholism (Oxford, Oxfordshire). vol 41. issue 4. 2006-12-15. PMID:16684847. |
this study examined the effects of aripiprazole, a novel atypical antipsychotic drug with partial agonist properties at dopamine d2 receptors, on the voluntary limited access alcohol drinking of alcohol-preferring aa (alko, alcohol) rats. |
2006-12-15 |
2023-08-12 |
rat |
| Martyn D Wood, Claire Scott, Kirsten Clarke, Katherine J Cato, Nisha Patel, Jennie Heath, Angela Worby, Laurie Gordon, Lorraine Campbell, Graham Riley, Ceri H Davies, Andrew Gribble, Declan N C Jone. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS & neurological disorders drug targets. vol 5. issue 4. 2006-09-29. PMID:16918396. |
the data produced has highlighted that the atypical profile of apd such as olanzapine and clozapine may reflect antagonism of the 5-ht(2a) and 5-ht(2c) receptors, whilst that of, ziprasidone and quetiapine may reflect partial agonist activity at the 5-ht(1a) receptor, and that of aripiprazole may reflect partial agonist activity at the 5-ht(1a) receptor as well as is its claimed partial agonist activity at the dopamine d(2) receptor. |
2006-09-29 |
2023-08-12 |
Not clear |
| Sridhar Natesan, Greg E Reckless, José N Nobrega, Paul J Fletcher, Shitij Kapu. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 31. issue 9. 2006-09-28. PMID:16319908. |
dissociation between in vivo occupancy and functional antagonism of dopamine d2 receptors: comparing aripiprazole to other antipsychotics in animal models. |
2006-09-28 |
2023-08-12 |
Not clear |
| Michael J Burke, Jana Lincol. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 18. issue 2. 2006-08-24. PMID:16754419. |
aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. |
2006-08-24 |
2023-08-12 |
Not clear |